Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

[Achievement of low-density lipoprotein cholesterol therapeutic goal in lipid and vascular risk units of the Spanish Arteriosclerosis Society].

Pedro-Botet J, Mostaza JM, Pintó X, Banegas JR; En Nombre del Grupo de Investigadores EDICONDIS-ULISEA.

Clin Investig Arterioscler. 2013 Sep-Oct;25(4):155-63. doi: 10.1016/j.arteri.2013.07.006. Epub 2013 Sep 14. Spanish.

PMID:
24041476
2.

[LDL-cholesterol control in patients with genetic dyslipidemia followed up by Lipid and Vascular Risk Units of the Spanish Society of Arteriosclerosis].

Lahoz C, Mostaza JM, Pintó X, de la Cruz JJ, Banegas JR, Pedro-Botet J; grupo de investigadores EDICONDIS-ULISEA.

Clin Investig Arterioscler. 2015 Jan-Feb;27(1):1-8. doi: 10.1016/j.arteri.2014.04.001. Epub 2014 Jun 2. Spanish.

PMID:
24882148
3.

Lipid target achievement among patients with very high and high cardiovascular risk in a lipid clinic.

Barkas F, Liberopoulos EN, Kostapanos MS, Liamis G, Tziallas D, Elisaf M.

Angiology. 2015 Apr;66(4):346-53. doi: 10.1177/0003319714535073. Epub 2014 May 15.

PMID:
24830420
4.

Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.

Gitt AK, Drexel H, Feely J, Ferrières J, Gonzalez-Juanatey JR, Thomsen KK, Leiter LA, Lundman P, da Silva PM, Pedersen T, Wood D, Jünger C, Dellea PS, Sazonov V, Chazelle F, Kastelein JJ; DYSIS Investigators.

Eur J Prev Cardiol. 2012 Apr;19(2):221-30. doi: 10.1177/1741826711400545. Epub 2011 Mar 10.

PMID:
21450578
5.

The COSEHC™ Global Vascular Risk Management quality improvement program: first follow-up report.

Ferrario CM, Joyner J, Colby C, Exuzides A, Moore M, Simmons D, Bestermann W Jr, Frech-Tamas F.

Vasc Health Risk Manag. 2013;9:391-400. doi: 10.2147/VHRM.S44950. Epub 2013 Jul 22.

6.

Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.

Van Ganse E, Laforest L, Burke T, Phatak H, Souchet T.

Clin Ther. 2007 Aug;29(8):1671-81.

PMID:
17919548
7.

Achieving low-density lipoprotein cholesterol treatment goals among dyslipidemic individuals in the Levant: the CEntralized Pan-Levant survey on tHE Undertreatment of hypercholeSterolemia (CEPHEUS) study.

Hammoudeh AJ, Echtay A, Ghanem GY, Haddad J; CEPHEUS-Levant survey investigators.

Curr Med Res Opin. 2014 Oct;30(10):1957-65. doi: 10.1185/03007995.2014.929095. Epub 2014 Jun 18.

PMID:
24889279
8.

[Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease].

Pérez A, González Blanco C, Hernández-Presa MÁ, Chaves J.

Endocrinol Nutr. 2011 Jun-Jul;58(6):283-90. doi: 10.1016/j.endonu.2011.03.005. Spanish.

PMID:
21641286
9.

Long-term achievement of the therapeutic objectives of lipid-lowering agents in primary prevention patients and cardiovascular outcomes: an observational study.

Van Ganse E, Souchet T, Laforest L, Moulin P, Bertrand M, Le Jeunne P, Chretin S, Yin D, Alemao E, de Pouvourville G.

Atherosclerosis. 2006 Mar;185(1):58-64. Epub 2005 Jul 20.

PMID:
16038912
10.

Atherogenic dyslipidemia: prevalence and management in lipid clinics.

Pedro-Botet J, Flores-Le Roux JA, Mostaza JM, Pintó X, de la Cruz JJ, Banegas JR; en nombre del grupo de investigadores EDICONDIS-ULISEA.

Rev Clin Esp. 2014 Dec;214(9):491-8. doi: 10.1016/j.rce.2014.06.001. Epub 2014 Jul 9. English, Spanish.

PMID:
25016414
11.

Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey.

Park JE, Chiang CE, Munawar M, Pham GK, Sukonthasarn A, Aquino AR, Khoo KL, Chan HW.

Eur J Prev Cardiol. 2012 Aug;19(4):781-94. doi: 10.1177/1741826710397100. Epub 2011 Mar 7.

PMID:
21450606
12.

The CEPHEUS Pan-Asian survey: high low-density lipoprotein cholesterol goal attainment rate among hypercholesterolaemic patients undergoing lipid-lowering treatment in a Hong Kong regional centre.

Chan RH, Chan PH, Chan KK, Lam SC, Hai JJ, Wong MK, Tam FC, Lam L, Chan CW, Lam YM, Siu DC, Tse HF, Lee SW.

Hong Kong Med J. 2012 Oct;18(5):395-406.

13.

Management of risk factors among ambulatory patients at high cardiovascular risk in Canada: a follow-up study.

Elbarasi EA, Goodman SG, Yan RT, Tan MK, Hackam DG, Leiter LA, Langer A, Yan AT; Guidelines Oriented Approach in Lipid Lowering (GOALL) Registry and Vascular Protection (VP) Registry Investigators.

Can J Cardiol. 2013 Dec;29(12):1586-92. doi: 10.1016/j.cjca.2013.06.013. Epub 2013 Sep 13.

PMID:
24041994
14.

Attainment of normal lipid levels among high cardiovascular risk patients: pooled analysis of observational studies from the United Kingdom, Sweden, Spain and Canada.

Ambegaonkar BM, Bash LD, Chirovsky DR, Jameson K, Grant S, Nocea G, Pettersson B, Sazonov V.

Eur J Intern Med. 2013 Oct;24(7):656-63. doi: 10.1016/j.ejim.2013.07.005. Epub 2013 Aug 13.

PMID:
23953848
15.

Attainment of low-density lipoprotein cholesterol target in the French general population according to levels of cardiovascular risk: Insights from the MONA LISA study.

Bongard V, Dallongeville J, Arveiler D, Ruidavets JB, Amouyel P, Wagner A, Ferrières J.

Arch Cardiovasc Dis. 2013 Feb;106(2):93-102. doi: 10.1016/j.acvd.2012.11.003. Epub 2013 Jan 16.

16.

Cardiovascular risk factors and recommended lipid goals attainment among patients referred in a tertiary care lipid clinic.

Pirro M, Del Giorno R, Lupattelli G, Mannarino MR, Roscini AR, Covelli D, Schillaci G, Pasqualini L, Bagaglia F, Siepi D, Mannarino E.

Eur J Intern Med. 2011 Aug;22(4):412-7. doi: 10.1016/j.ejim.2011.04.007. Epub 2011 May 26.

PMID:
21767761
17.

Current cardiovascular risk management patterns with special focus on lipid lowering in daily practice in Switzerland.

Jaussi A, Noll G, Meier B, Darioli R.

Eur J Cardiovasc Prev Rehabil. 2010 Jun;17(3):363-72. doi: 10.1097/HJR.0b013e328333c1d9.

PMID:
20168234
18.

Status of dyslipidemia treatment in Japanese adults: an analysis of the 2009 Japan Society of Ningen Dock database.

Takahashi E, Moriyama K, Yamakado M.

Intern Med. 2013;52(3):295-301. Epub 2013 Feb 1.

19.

Optimal management of combined dyslipidemia: what have we behind statins monotherapy?

Tenenbaum A, Fisman EZ, Motro M, Adler Y.

Adv Cardiol. 2008;45:127-53. doi: 10.1159/0000115192. Review.

PMID:
18230960
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk